Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part B Demo Comments Overwhelmingly Negative, Uniform In Content

Executive Summary

More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.

Advertisement

Related Content

CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does
Trump, Congress And The Future Of Value-Based Drug Contracting
Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less
Medicare Part B Demo Partially Shielded From Congress By CBO Scoring
Copay Coupons May Skew Medicare Part B Reimbursement, GAO Says
Who’s Afraid Of Payment Reform? CMS Cardiac Bundle Shows How Changes Can Be Positive For Rx

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel